John Wang | Chief Scientific Officer
Kali Therapeutics

Dr. John Wang is the Co-founder and Chief Scientific Officer of Kali Therapeutics. Before co-founding Kali, Dr. Wang dedicated his career to developing innovative immunotherapies for leukemia and other cancers in both academia and the biotech, contributing to multiple therapeutic programs that advanced into clinical development. At Kali Therapeutics, Dr. Wang leads the company's research and early discovery efforts, focusing on the development of next-generation immune therapies for serious diseases. In early 2026, KT501—a trispecific antibody developed using Kali's proprietary T-cell engager (TCE) technology—was licensed to Sanofi, representing a significant milestone for the company and validating its innovative platform.